Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study
Cancer Communications · 2026
DOI: 10.34133/cancomm.0037 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Communications, 2026. Verfasst von Lina Zhang und 43 weiteren Autor:innen. Beteiligte Einrichtung: Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China. Hauptthemen laut MEDLINE: Breast Neoplasms, Albumin-Bound Paclitaxel, Paclitaxel, Antineoplastic Agents, Phytogenic. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CSPC Ouyi Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Background
SYHX2011 is a novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose. This study aimed to compare SYHX2011 and paclitaxel for injection (albumin-bound) (PAB) in patients with breast cancer.
Methods
Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic breast cancer were randomly assigned to receive SYHX2011 (260 mg/m 2 ) or PAB (260 mg/m 2 ) intravenously once every 3 weeks, stratified by prior taxane use and rash history (prior taxane with rash, prior taxane without rash, or no prior taxane), as well prior lines of chemotherapy for advanced disease (0 or ≥1). The primary endpoint was objective response rate assessed by an independent review committee. Noninferiority was to be declared if the lower bound of the 95% confidence interval (CI) for the rate ratio exceeded 0.75; if the lower bound exceeded 1, superiority would subsequently be tested and considered confirmed.
Results
In this multicenter, randomized, double-blind, phase III trial across 56 centers in China, 621 patients were screened between 2023 April 23 and 2024 March 21, of whom 459 patients were randomized to SYHX2011 ( n = 229) or PAB ( n = 230). The confirmed objective response rate assessed by an independent review committee was 35.8% (95% CI 29.4% to 42.6%) for SYHX2011 and 25.8% (95% CI 20.2% to 32.1%) for PAB (rate ratio = 1.38, 95% CI 1.04 to 1.84; one-sided P = 0.012), indicating that SYHX2011 was noninferior to PAB. The superiority of SYHX2011 over PAB was also confirmed. SYHX2011 showed a lower incidence of rash compared with PAB during the first 2 administration cycles (13.6% vs. 34.3%) and all treatment cycles (16.2% vs. 42.6%). Treatment-related adverse events (TRAEs) occurred in 98.2% of patients receiving SYHX2011 and 98.3% of patients receiving PAB. In the SYHX2011 group, 111 (48.7%) patients experienced grade ≥3 TRAEs, compared with 101 (43.9%) patients in the PAB group. The most common grade ≥3 TRAEs were neutropenia, leukopenia, and peripheral sensory neuropathy. The median investigational drug reconstitution time was 2.0 min for SYHX2011 and 11.0 min for PAB.
Conclusions
SYHX2011 demonstrated greater therapeutic benefits than PAB and significantly reduced the incidence of rash. Additionally, it could offer greater convenience in clinical application, providing advanced breast cancer patients with more effective and safer treatment options.
Trial registration
ClinicalTrials.gov identifier: NCT05753865. Date of registration: 2023 February 22.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.
- Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China.
- Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.
- Department of Medical Oncology, Xinjiang Medical University Affiliated Cancer Hospital, Urumqi, Xinjiang, P. R. China.
- Department of Medical Oncology, Shanxi Cancer Hospital, Taiyuan, Shanxi, P. R. China.
ORCID-Profile: Cuizhi Geng
Förderung
- CSPC Ouyi Pharmaceutical Co., Ltd
Zitieren
APA
Zhang, L., Wang, J., Sun, T., Li, F., Zhao, B., Han, G., Tong, Z., Yang, H., Yin, Y., Kong, X., Wang, Y., Nie, J., Ma, L., Zhang, Y., Luo, J., Shan, C., Yao, J., Tan, S., Ling, X., …, & Geng, C. (2026). Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study. Cancer Communications. https://doi.org/10.34133/cancomm.0037
Vancouver
Zhang L, Wang J, Sun T, Li F, Zhao B, Han G, et al. Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study. Cancer Communications. 2026. doi:10.34133/cancomm.0037
BibTeX
@article{Zhang2026,
author = {Zhang, Lina and Wang, Jingxuan and Sun, Tao and Li, Fanfan and Zhao, Bing and Han, Guohui and Tong, Zhongsheng and Yang, Hua and Yin, Yongmei and Kong, Xiangshun and Wang, Ying and Nie, Jianyun and Ma, Lixia and Zhang, Yongqiang and Luo, Jing and Shan, Changping and Yao, Jing and Tan, Shisheng and Ling, Xiaoling and Sun, Hongmei and Li, Huihui and Ma, Li and Zhou, Tao and Liu, Yunjiang and Qi, Yixin and Song, Zhenchuan and Li, Yuntao and Yang, Chao and Hui, Tianli and Wang, Meiqi and Wang, Haoqi and Zhang, Xi and Zhao, Wenhui and Li, Yanhui and Li, Mengmeng and Xin, Ying and Luo, Xuan and Yin, Deliang and Luo, Hongmei and Liu, Huan and Lu, Qianyun and Yuan, Jing and Zhang, Qingyuan and Geng, Cuizhi},
title = {Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study},
journal = {Cancer Communications},
year = {2026},
doi = {10.34133/cancomm.0037}
}
EUVIMED